Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH - Free Report) - Investment analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for Reviva Pharmaceuticals in a research report issued to clients and investors on Monday, April 22nd. HC Wainwright analyst R. Selvaraju forecasts that the company will earn ($0.33) per share for the quarter. HC Wainwright has a "Buy" rating and a $20.00 price objective on the stock. The consensus estimate for Reviva Pharmaceuticals' current full-year earnings is ($0.92) per share. HC Wainwright also issued estimates for Reviva Pharmaceuticals' Q2 2025 earnings at ($0.31) EPS, Q3 2025 earnings at ($0.24) EPS and Q4 2025 earnings at ($0.21) EPS.
Separately, Benchmark reiterated a "speculative buy" rating and issued a $17.00 price target on shares of Reviva Pharmaceuticals in a report on Tuesday, April 16th.
Get Our Latest Research Report on Reviva Pharmaceuticals
Reviva Pharmaceuticals Trading Down 1.0 %
Shares of NASDAQ RVPH traded down $0.03 during midday trading on Tuesday, hitting $3.06. The company's stock had a trading volume of 77,792 shares, compared to its average volume of 312,741. The business's 50 day moving average is $3.60 and its two-hundred day moving average is $4.11. Reviva Pharmaceuticals has a 12-month low of $2.67 and a 12-month high of $9.25. The firm has a market cap of $85.44 million, a P/E ratio of -1.87 and a beta of -0.02.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently bought and sold shares of RVPH. Vontobel Holding Ltd. bought a new position in Reviva Pharmaceuticals in the fourth quarter worth approximately $72,000. EMC Capital Management boosted its position in Reviva Pharmaceuticals by 1,294.3% during the 3rd quarter. EMC Capital Management now owns 123,915 shares of the company's stock valued at $613,000 after acquiring an additional 115,028 shares in the last quarter. Finally, Armistice Capital LLC boosted its position in Reviva Pharmaceuticals by 194.0% during the 4th quarter. Armistice Capital LLC now owns 1,764,000 shares of the company's stock valued at $9,085,000 after acquiring an additional 1,164,000 shares in the last quarter. Institutional investors own 63.18% of the company's stock.
Reviva Pharmaceuticals Company Profile
(
Get Free Report)
Reviva Pharmaceuticals Holdings, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is brilaroxazine (RP5063), which is in Phase III clinical trials for use in the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis.
See Also
Before you consider Reviva Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Reviva Pharmaceuticals wasn't on the list.
While Reviva Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
